Skip to main content
  • DRDO develops SpO2 based Supplemental Oxygen Delivery System

    Defence Research and Development Organisation has developed SpO2 Blood Oxygen Saturation supplemental Oxygen Delivery System for soldiers posted at extreme high-altitude areas. Developed by Defence Bio-Engineering & Electro Medical Laboratory, Bengaluru of DRDO, the system delivers supplemental oxygen based on the SpO2 levels and prevents the person from sinking in to a state of Hypoxia, which is fatal in most cases, if sets in. This automatic system can also prove to be a boon during the current Covid-19 situation.

    admin Tue, 04/20/2021 - 16:47
  • Jubilant Pharma develops Oral Remedesivir

    Jubilant Pharma Limited, a subsidiary of Jubilant Pharmova Limited, announces successful completion of safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India using a novel oral formulation of remdesivir against the commercially available injectable formulation of remdesivir.

    admin Tue, 04/20/2021 - 16:39
  • Two Blood Thinners at Once : More Risk with the Same Reward

    More blood thinners arent automatically better, another study confirms. A new publication in JAMA Internal Medicine focuses on the minimal pros and the concerning cons of combining a daily aspirin with a drug from the newer class of anticoagulants that include apixaban, dabigatran, edoxaban and rivaroxaban.

    admin Tue, 04/20/2021 - 16:24
  • Scientists identify protein that could serve as a therapeutic target in lung cancer

    Scientists at VCU Massey Cancer Center have identified a protein that operates in tandem with a specific genetic mutation to spur lung cancer growth and could serve as a therapeutic target to treat the disease.

    admin Tue, 04/20/2021 - 16:19
  • Thermo Fisher Scientific to Acquire PPD, Inc

    Thermo Fisher Scientific Inc the world leader in serving science, and PPD, Inc a leading global provider of clinical research services to the pharma and biotech industry announced that their boards of directors have approved a definitive agreement under which Thermo Fisher will acquire PPD for $47.50 per share for a total cash purchase price of $17.4 billion plus the assumption of approximately $3.5 billion of net debt.

    admin Mon, 04/19/2021 - 15:59
  • Evobrutinib is the First and Only BTK Inhibitor for Multiple Sclerosis

    Merck, a leading science and technology company, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology Annual Meeting showing that the investigational Bruton’s tyrosine kinase inhibitor evobrutinib significantly reduced blood neurofilament light chain  evels, a key biomarker of neuronal damage and inflammation, in patients with multiple sclerosis (MS).

    admin Mon, 04/19/2021 - 15:41
  • Vaccination is not meant for preventing the infection, it is meant for preventing the outcome of Infection

    The production of the vaccine should be augmented and more and more people should be covered for vaccination. The manufacturing needs to scale up and distribution needs to happen at a fast pace, mentioned Dr. D C Katoch, Chief Medical Officer, CGHS, Ministry of Health & Family Welfare, Govt. of India in an awareness webinar organized by PHD Chamber of Commerce and Industry on Importance of Tika Utsav- Covid Vaccination.

    admin Sat, 04/17/2021 - 16:16
  • A new treatment for rare muscular disease

    Rare diseases are sometimes the most difficult to treat because of a lack of research and fewer participants to study. An example would be those who have Pompe disease, a genetic condition when a body can't make a protein that breaks down a complex sugar, called glycogen, for energy. Too much glycogen builds up and damages muscles and organs. The disease causes muscle weakness and trouble breathing and can affect the heart and muscles.

    admin Fri, 04/16/2021 - 15:55
  • Triangular-shaped spikes key to coronavirus transmission, finds new study

    COVID-19 needs no introduction. Last year, the disease, which is caused by the virus SARS-CoV-2, reached every continent across the globe. By the end of March 2021, there had been an estimated 128 million cases recorded with almost three million of these being fatal. As scientists' race to develop vaccines and politicians coordinate their distribution, fundamental research on what makes this virus so successful is also being carried out.

    admin Fri, 04/16/2021 - 15:50
  • Some antibodies can broadly neutralize ebolaviruses ; Study

    Some survivors of ebolavirus outbreaks make antibodies that can broadly neutralize these viruses--and now, scientists at Scripps Research have illuminated how these antibodies can disable the viruses so effectively. The insights may be helpful for developing effective therapies.

    admin Fri, 04/16/2021 - 15:44
Subscribe to Pharma News